Design and development of novel therapeutics for coronary heart disease treatment based on cholesteryl ester transfer protein inhibition - in silico approach

被引:4
|
作者
Kostic, Tomislav [1 ]
Ilic, Marina Deljanin [2 ]
Perisic, Zoran [1 ]
Milic, Dragan [3 ]
Dordevic, Miodrag [4 ]
Golubovic, Mladjan [5 ]
Koracevic, Goran [1 ]
Martinovic, Sonja Salinger [1 ]
Zdravkovic, Snezana Ciric [1 ]
Zivic, Sasa [3 ]
Lazarevic, Milan [3 ]
Stanojevic, Dragana [1 ]
Dakic, Sonja [1 ]
Lilic, Jelena [5 ]
Veselinovic, Aleksandar [6 ]
机构
[1] Clin Ctr Nis, Clin Cardiovasc Dis, Nish, Serbia
[2] Inst Cardiovasc Prevent & Rehabil Niska Banja, Nish, Serbia
[3] Clin Ctr Nis, Clin Cardiovasc Surg, Nish, Serbia
[4] Clin Ctr Nis, Clin Endocrine Surg & Breast Surg, Nish, Serbia
[5] Clin Ctr Nis, Clin Anesthesiol & Intens Care, Nish, Serbia
[6] Univ Nis, Fac Med, Dept Chem, Bulevar Dr Zorana Dindica 81, Nish 18000, Serbia
来源
关键词
Cholesteryl ester transfer protein inhibitors; coronary heart disease therapy; QSAR; molecular modeling; drug design; MONTE-CARLO METHOD; DRUG DISCOVERY; VARIABLE SELECTION; QSAR; HDL; VALIDATION; PRINCIPLES; DOCKING; 3D-QSAR; TARGET;
D O I
10.1080/07391102.2019.1630319
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cholesteryl ester transfer protein (CETP) belongs to the group of enzymes which inhibition have the application in the treatment of cardiovascular diseases. This study presents QSAR modeling for a set of compounds acting as CETP inhibitors based on the Monte Carlo optimization with SMILES notation and molecular graph-based descriptors, and field-based 3D modeling. A 3D QSAR model was developed for one random split into the training and test sets, whereas conformation independent QSAR models were developed for three random splits, with the results suggesting there is an excellent correlation between them. Various statistical approaches were used to assess the statistical quality of the developed models, including robustness and predictability, and the obtained results were very good. This study used a novel statistical metric known as the index of ideality of correlation for the final assessment of the model, and the results that were obtained suggested that the model was good. Also, molecular fragments which account for the increases and/or decreases of a studied activity were defined and then used for the computer-aided design of new compounds as potential CETP inhibitors. The final assessment of the developed QSAR model and designed inhibitors was done using molecular docking, which revealed an excellent correlation with the results from QSAR modeling. Communicated by Ramaswamy H. Sarma
引用
收藏
页码:2304 / 2313
页数:10
相关论文
共 50 条
  • [41] Genetic variations of cholesteryl ester transfer protein and diet interactions in relation to lipid profiles and coronary heart disease: a systematic review
    Mirmiran, Parvin
    Esfandiar, Zohre
    Hosseini-Esfahani, Firoozeh
    Koochakpoor, Gelareh
    Daneshpour, Maryam S.
    Sedaghati-Khayat, Bahar
    Azizi, Fereidoun
    NUTRITION & METABOLISM, 2017, 14
  • [42] Genetic variations of cholesteryl ester transfer protein and diet interactions in relation to lipid profiles and coronary heart disease: a systematic review
    Parvin Mirmiran
    Zohre Esfandiar
    Firoozeh Hosseini-Esfahani
    Gelareh Koochakpoor
    Maryam S. Daneshpour
    Bahar Sedaghati-Khayat
    Fereidoun Azizi
    Nutrition & Metabolism, 14
  • [43] Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia
    Bruce, C
    Sharp, DS
    Tall, AR
    JOURNAL OF LIPID RESEARCH, 1998, 39 (05) : 1071 - 1078
  • [44] Cholesteryl ester transfer protein gene haplotypes, plasma high-density lipoprotein levels and the risk of coronary heart disease
    McCaskie, Pamela A.
    Beilby, John P.
    Chapman, Caroline M. L.
    Hung, Joseph
    McQuillan, Brendan M.
    Thompson, Peter L.
    Palmer, Lyle J.
    HUMAN GENETICS, 2007, 121 (3-4) : 401 - 411
  • [45] Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease?
    Nicholls, Stephen J.
    Nelson, Adam J.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2019, 19 (03) : 229 - 235
  • [46] Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease?
    Stephen J. Nicholls
    Adam J. Nelson
    American Journal of Cardiovascular Drugs, 2019, 19 : 229 - 235
  • [47] Raising high-density lipoprotein cholesterol with inhibitors of cholesteryl ester transfer protein - a new approach to coronary artery disease
    Doggrell, SA
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (10) : 1365 - 1368
  • [48] Plasma lecithin-cholesteryl acyl transferase and cholesteryl ester transfer protein activity in angiographically confirmed coronary artery disease
    Yesilbursa, D
    Serdar, Z
    Dirican, M
    Serdar, A
    Güllülü, S
    Coskun, S
    Baran, I
    Cordan, J
    ATHEROSCLEROSIS, 1999, 146 : S37 - S37
  • [49] Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
    Schaefer, Ernst J.
    CURRENT OPINION IN LIPIDOLOGY, 2013, 24 (03) : 259 - 264
  • [50] Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk -: The Framingham study
    Ordovas, JM
    Cupples, LA
    Corella, D
    Otvos, JD
    Osgood, D
    Martinez, A
    Lahoz, C
    Coltell, O
    Wilson, PWF
    Schaefer, EJ
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (05) : 1323 - 1329